News AbbVie takes option on Argenx's cancer immunotherapy ARGX-115 is still in preclinical development
Views & Analysis Oncolytics: the dawn of a new era in cancer treatment Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunothera
News Novel cancer immunotherapy research lands Innovate UK fundin... New programme will leverage well-validated genetic mechanisms to promote cancer immunity.
News BI strikes billion-dollar cancer immunotherapy deal with OSE Could BI be looking to develop combination therapy?
News Roche's Tecentriq halts disease in squamous lung cancer Roche’s cancer immunotherapy Tecentriq has produced strong results which could give it the lead in a key lung cancer indication.
News Big pharma could turn to viruses to boost cancer immunothera... Norwegian biotech looking for development partners
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
